The FDA approval of Orlynvah is a major milestone for Iterum Therapeutics as it is their first approved product. This approval not only validates their clinical development efforts but also opens up new opportunities for strategic partnerships, which could enhance the company's market position and financial performance. Despite the stock being down, the approval is likely to have a positive impact on the stock price in the short term as it represents a significant achievement and potential for future growth.